References of "Annals of Internal Medicine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailACP Journal Club: supplementation with vitamin D did not reduce cartilage volume loss or pain in knee osteoarthritis.
REGINSTER, Jean-Yves ULg; Pelousse, Franz

in Annals of Internal Medicine (2013), 158(8), 9

Detailed reference viewed: 10 (5 ULg)
Full Text
Peer Reviewed
See detailTwo novel equations to estimate kidney function in persons aged 70 years or older
Schaeffner, Elke; Ebert, Natalie; DELANAYE, Pierre ULg et al

in Annals of Internal Medicine (2012), 157(7), 471-481

Detailed reference viewed: 26 (0 ULg)
Full Text
Peer Reviewed
See detailCystatin C, renal function, and cardiovascular risk.
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Krzesinski, Jean-Marie ULg

in Annals of Internal Medicine (2008), 148(4), 323

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailRisk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
El-Sadr, W. M.; Grund, B.; Neuhaus, J. et al

in Annals of Internal Medicine (2008), 149(5), 289-99

BACKGROUND: Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy. OBJECTIVE: To determine whether reinitiating continuous antiretroviral ... [more ▼]

BACKGROUND: Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy. OBJECTIVE: To determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease or death. DESIGN: Randomized, controlled trial. SETTING: Sites in 33 countries. PATIENTS: 5472 HIV-infected individuals with CD4(+) cell counts greater than 0.350 x 10(9) cells/L enrolled from January 2002 to January 2006. INTERVENTION: Episodic or continuous antiretroviral therapy initially, followed by continuous therapy in participants previously assigned to episodic treatment. MEASUREMENTS: Opportunistic disease or death was the primary outcome. RESULTS: Eighteen months after the recommendation to reinitiate continuous therapy, mean CD4+ cell counts were 0.152 x 10(9) cells/L (95% CI, 0.136 to 0.167 x 10(9) cells/L) less in participants previously assigned to episodic treatment (P < 0.001). The proportion of follow-up time spent with CD4+ cell counts of 0.500 x 10(9) cells/L or more and HIV RNA levels of 400 copies/mL or less was 29% for participants initially assigned to episodic therapy and 66% for those assigned to continuous therapy. Participants who reinitiated continuous therapy experienced rapid suppression of HIV RNA levels (89.7% with HIV RNA levels < or =400 copies/mL after 6 months), but CD4+ cell counts after 6 months remained 0.140 x 10(9) cells/L below baseline. The hazard ratio (episodic versus continuous treatment) for opportunistic disease or death decreased after the recommendation to reinitiate continuous therapy (from 2.5 [CI, 1.8 to 3.5] to 1.4 [CI, 1.0 to 2.0]; P = 0.033 for difference). The residual excess risk was attributable to failure to reinitiate therapy by some participants and slow recovery of CD4+ cell counts for those who reinitiated therapy. LIMITATION: Follow-up was too short to assess the full effect of switching from episodic to continuous antiretroviral therapy. CONCLUSION: Reinitiating continuous antiretroviral therapy in patients previously assigned to episodic treatment reduced excess risk for opportunistic disease or death, but excess risk remained. Episodic antiretroviral therapy, as used in the SMART study, should be avoided. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailEstimated glomerular filtration rate
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Krzesinski, Jean-Marie ULg

in Annals of Internal Medicine (2007), 146(1), 74-74

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailThe new Mayo clinic equation for estimating glomerular filtration rate
Delanaye, Pierre ULg; Krzesinski, Jean-Marie ULg

in Annals of Internal Medicine (2005), 142(8), 679-680

Detailed reference viewed: 16 (6 ULg)
Full Text
Peer Reviewed
See detailFluoride for the treatment of osteoporosis
Reginster, Jean-Yves ULg

in Annals of Internal Medicine (1999), 130

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailThe Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial
Reginster, Jean-Yves ULg; Meurmans, L.; Zegels, Brigitte ULg et al

in Annals of Internal Medicine (1998), 129(1), 1-8

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are ... [more ▼]

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are controversial. OBJECTIVE: To study the effect of low-dose fluoride (sodium monofluorophosphate [MFP]) plus a calcium supplement over 4 years on vertebral fractures and BMD at the lumbar spine and total hip in postmenopausal women with moderately low BMD of the spine. DESIGN: Randomized, double-blind, controlled clinical trial. SETTING: Outpatient clinic for osteoporosis at a university medical center. PATIENTS: 200 postmenopausal women with osteoporosis (according to the World Health Organization definition) and a T-score less than -2.5 for BMD of the spine. INTERVENTION: Women were randomly assigned (100 patients per group) to continuous daily treatment for 4 years with 1) oral MFP (20 mg of equivalent fluoride) plus 1000 mg of calcium (as calcium carbonate) or 2) calcium only. MEASUREMENTS: Lateral spine radiographs were taken at enrollment and at each year of follow-up for detection of new vertebral fractures (defined as a reduction > or =20% and > or =4 mm from baseline in any of the heights of a vertebral body). Nonvertebral fractures were also recorded. All analyses were done with the intention-to-treat approach. RESULTS: Radiologic follow-up was possible for 164 of 200 patients (82%). The rate of new vertebral fractures during the 4 years of the study was lower in the MFP-plus-calcium group (2 of 84 patients; 2.4% [95% CI, 0.3% to 8.3%]) than in the calcium-only group (8 of 80 patients; 10% [CI, 4.4% to 18.8%]). The difference between the groups was 7.6 percentage points (CI, 0.3 to 15 percentage points) (P = 0.05). A moderate but progressive increase in BMD of the spine (10.0% +/- 1.5% at 4 years) was found for MFP plus calcium compared with calcium only (P < 0.001), whereas the more modest increase in BMD of the total hip seen with MFP plus calcium (1.8% +/- 0.6%) did not differ from the increase seen with calcium only. CONCLUSIONS: Low-dose fluoride (20 mg/d) given continuously with calcium for prolonged periods can decrease vertebral fracture rates compared with calcium alone in patients with mild to moderate osteoporosis. [less ▲]

Detailed reference viewed: 10 (4 ULg)
See detailTreatment of TSH-secreting pituitary adenomas with octreotide : A floow-up of 52 patients
Chanson, Philippe; Weintraub, Bruce D; Harris, Alan G et al

in Annals of Internal Medicine (1993), 119(3), 236-240

Detailed reference viewed: 4 (0 ULg)